Satellos Bioscience annual ebitda
2022
2024
2025
Satellos Bioscience EBITDA Growth & History (MSLE)
Satellos Bioscience's calculated EBITDA was −$26.5M for fiscal 2025.
View full Satellos Bioscience company overviewSatellos Bioscience annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$26.5M | −$6.1M | — |
| 2024 | 2024-12-31 | −$20.4M | — | — |
| 2022 | 2022-12-31 | −$8.1M | — | — |
Satellos Bioscience quarterly ebitda
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$12.2M | −$5.8M | — |
| Q1 2026 | 2026-03-31 | −$10.0M | −$3.6M | — |
| Q4 2025 | 2025-12-31 | −$7.6M | — | — |
| Q3 2025 | 2025-09-30 | −$6.0M | — | — |
| Q2 2025 | 2025-06-30 | −$6.4M | — | — |
| Q1 2025 | 2025-03-31 | −$6.5M | — | — |
Satellos Bioscience ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Satellos Bioscience's ebitda decreased from −$8.1M to −$26.5M, a change of −$18.4M. The latest reported quarter, Q2 2026, shows −$12.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Satellos Bioscience source filings ↗Community posts
Satellos clears FDA hurdle for a new muscular-dystrophy trial
Satellos Bioscience ($MSLE) received FDA clearance for its investigational application to study forazapadin in facioscapulohumeral muscular dystrophy. The company plans to start a randomized, placebo-controlled Phase 2 study in the fourth q ...
